跳至主要内容
临床试验/ISRCTN54581790
ISRCTN54581790已完成4 期

Efficacy and safety of Cerebrolysin in the treatment of aphasia after acute ischemic stroke

The foundation for the study of neuroscience and neuroregeneration (SSNN)0 个研究点目标入组 132 人开始时间: 2020年4月29日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
132

研究概览

简要总结

2024 Preprint results in https://doi.org/10.1101/2024.02.23.24303302 (added 19/08/2024)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 04/06/2020:
  • 1. Radiologically (CT or MRI) and clinically confirmed diagnosis of acute ischemic stroke in the left MCA territory
  • 2. Broca or mixed non-fluent aphasia
  • 3. Inclusion in the study between 3 and 5 days post-stroke
  • 4. Right-handedness
  • 5. Romanian as language of daily use
  • 6. Signed informed consent
  • Previous inclusion criteria:
  • 1. Radiologically (CT or MRI) and clinically confirmed diagnosis of acute ischemic stroke in the left MCA territory
  • 2. Broca or mixed non-fluent aphasia
  • 3. Inclusion in the study between 5 and 30 days post-stroke
  • 4. Right-handedness
  • 5. Romanian as language of daily use
  • 6. Signed informed consent

排除标准

  • 1. Prior symptomatic ischemic or hemorrhagic stroke
  • 2. Severe comprehension deficit that may compromise informed consent or understanding of instructions such as fluent aphasias (ex. Wernicke aphasia), or global aphasias
  • 3. Contraindications to MRI
  • 4. Preexisting neurodegenerative or psychiatric disease
  • 5. Epilepsy or EEG-documented epileptic discharges
  • 6. Severe chronic renal or liver failure; (AST, ALT > 4 times normal values, creatinine > 4)
  • 7. Life-threatening diseases
  • 8. Auditory or visual deficits that cannot be corrected and might impair testing

研究者

发起方
The foundation for the study of neuroscience and neuroregeneration (SSNN)

相似试验